2017
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors
Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O’Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors. Advances In Anatomic Pathology 2017, 24: 235-251. PMID: 28777142, PMCID: PMC5564448, DOI: 10.1097/pap.0000000000000162.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesTIL assessmentInvasive breast carcinomaSolid tumor typesBreast carcinomaSolid tumorsTumor typesDifferent solid tumor typesForm of immunotherapyImmune checkpoint inhibitorsEra of immunotherapyImportant prognostic informationRoutine clinical biomarkersHost immune responseWorking Group guidelinesDiverse solid tumor typesCheckpoint inhibitorsMetastatic settingPrognostic informationGroup guidelinesImmune responseEosin sectionsHistopathologic specimensClinical validityPredictive significance
2005
Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer
Psyrri A, Kassar M, Yu Z, Bamias A, Weinberger PM, Markakis S, Kowalski D, Camp RL, Rimm DL, Dimopoulos MA. Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer. Clinical Cancer Research 2005, 11: 8637-8643. PMID: 16361548, DOI: 10.1158/1078-0432.ccr-05-1436.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorOvarian cancerOverall survivalPrognostic valuePlatinum-paclitaxel combination chemotherapyAdvanced stage ovarian cancerDisease-free survivalSignificant prognostic factorsAdverse prognostic indicatorEpithelial ovarian cancerTumor EGFR expressionEGFR expression statusImportant prognostic informationConflicting resultsEpidermal growth factor receptor expression levelsEGFR protein expressionReceptor expression levelsGrowth factor receptorSurgical debulkingCombination chemotherapyPrognostic factorsMultivariable analysisEntire cohortPoor outcomePrognostic indicator